Repligen Corporation (NASDAQ:RGEN) – Equities research analysts at First Analysis raised their FY2017 earnings estimates for shares of Repligen Corporation in a report released on Wednesday. First Analysis analyst now forecasts that the biotechnology company will post earnings of $0.60 per share for the year, up from their previous forecast of $0.55. First Analysis has a “Equal Weight” rating and a $40.00 price objective on the stock. First Analysis also issued estimates for Repligen Corporation’s Q4 2017 earnings at $0.16 EPS and FY2018 earnings at $0.72 EPS.
RGEN has been the subject of a number of other reports. Janney Montgomery Scott boosted their price objective on shares of Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a report on Thursday, May 11th. BidaskClub lowered shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC restated a “hold” rating and issued a $40.00 price objective (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Finally, William Blair began coverage on shares of Repligen Corporation in a report on Friday, July 21st. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Repligen Corporation currently has an average rating of “Buy” and a consensus price target of $42.00.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/08/13/fy2017-eps-estimates-for-repligen-corporation-rgen-increased-by-analyst.html.
Repligen Corporation (NASDAQ:RGEN) opened at 41.18 on Friday. The firm has a market capitalization of $1.54 billion, a PE ratio of 80.59 and a beta of 1.30. The firm has a 50-day moving average of $41.91 and a 200 day moving average of $36.63. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81.
Repligen Corporation (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The firm had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. During the same period in the prior year, the company posted $0.16 EPS. The company’s revenue was up 11.0% on a year-over-year basis.
A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its stake in Repligen Corporation by 3.7% in the second quarter. BlackRock Inc. now owns 4,834,853 shares of the biotechnology company’s stock worth $200,355,000 after buying an additional 170,551 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in Repligen Corporation by 19.8% in the second quarter. TimesSquare Capital Management LLC now owns 2,361,270 shares of the biotechnology company’s stock worth $97,851,000 after buying an additional 390,545 shares in the last quarter. Vanguard Group Inc. raised its stake in Repligen Corporation by 9.7% in the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after buying an additional 175,191 shares in the last quarter. FMR LLC raised its stake in Repligen Corporation by 6.2% in the second quarter. FMR LLC now owns 1,334,090 shares of the biotechnology company’s stock worth $55,285,000 after buying an additional 78,060 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its stake in Repligen Corporation by 6.3% in the second quarter. Conestoga Capital Advisors LLC now owns 1,291,805 shares of the biotechnology company’s stock worth $53,532,000 after buying an additional 75,995 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.